Study record
NIA Interventions Testing Program (ITP) 2009 rapamycin cohort
Age at 90% mortality (90th-percentile lifespan); median lifespan
Mus musculus (UM-HET3, genetically heterogeneous) — Multi-site NIA ITP cohort (Jackson Laboratory, University of Michigan, University of Texas sites) Tier 5 · Replicated animal lifespan verification: verified
1. Species / populationGenetically heterogeneous UM-HET3 mice, 3 NIA ITP test sites
2. Exposure, route, schedule~14 ppm in chow, begun at ~600 days of age (late-life start)
3. Comparator & durationControl chow, same-age cohort; followed to natural death
4. Endpoint & numeric resultAge at 90% mortality +14% (female) / +9% (male) at ~14 ppm in chow; replicated at 3 independent ITP sites
5. What this study did NOT establishNo human lifespan data; no dosing-equivalence or safety data for human 'longevity' use
Full record
| Intervention(s) | Rapamycin |
| Species | Mus musculus (UM-HET3, genetically heterogeneous) |
| Population | Multi-site NIA ITP cohort (Jackson Laboratory, University of Michigan, University of Texas sites) |
| Sample size | not specified in source animals verification: verified_2026-07-11 |
| Exposure | ~14 ppm in chow — Initiated at ~600 days of age (late-life start) verification: verified_2026-07-11 |
| Comparator | Control chow, same-age cohort |
| Duration | Followed to natural death (lifespan study) |
| Endpoint | Age at 90% mortality (90th-percentile lifespan); median lifespan |
| Evidence tier | Tier 5 · Replicated animal lifespan |
| What was NOT established | Did not test human lifespan, human dose equivalence, or safety of any 'longevity dose' in humans. Late-life initiation in mice does not establish outcomes for earlier-life human initiation. Does not establish an optimal or safe rapamycin dosing schedule for humans. |
Result values (as reported in sourcing brief)
| metric | age at 90% mortality (90th-percentile lifespan) |
| female change at 90pct mortality | +14% |
| male change at 90pct mortality | +9% |
| replication | Replicated across 3 independent ITP test sites |
| separation note | This record is the 2009 single-dose report at ~14 ppm only. The 42-ppm dose-response figures are a separate 2014 study (Miller et al., Aging Cell) and live on itp-doseresponse-rapamycin. The two also measure different quantities: 90%-mortality age here, median lifespan there. |
| verification | verification: verified_2026-07-11 |
Source citation
Verification status: verified This record was checked against its primary publication on 2026-07-11. PubMed/PMC/Lancet lookup; numbers cross-checked against abstract.Identifiers: PMID verified; DOI verified; PMC verified; trial registry ID not applicable. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that does not apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
| program | NIA Interventions Testing Program (ITP) |
| reported year | 2009 |
| pmid | 19587680 verified |
| doi | 10.1038/nature08221 verified |
| journal | Nature |
| pmc | PMC2786175 verified |
| authors | Harrison DE, Strong R, Sharp ZD, et al. (NIA ITP) |
| year | 2009 |
| verified date | 2026-07-11 |
| verified method | PubMed/PMC/Lancet lookup; numbers cross-checked against abstract |
| verified note | +14% female / +9% male lifespan at 90%-mortality age, ~14 ppm (14.7 mg/kg food), initiated 600 days, replicated 3 sites — MATCHES abstract. |
| correction | Dose-response arm (4.7/14/42 ppm) belongs to the SEPARATE 2014 Miller study (itp-doseresponse-rapamycin), not this 2009 single-dose report; do not attribute 42-ppm figures to Harrison 2009. |
| verification status | verified |
| reverified 20260808 | DOI re-confirmed against Crossref 2026-08-08 (Nature 460:392-395, author list matches). |
Funding / conflict of interest
not compiled in this proof-of-concept verification: verified_2026-07-11
Version 0.1.0-poc · literature search date 2026-07-11 · editorial owner Nabus Research